How It All Plays Out: Latest Research on PAREXEL, Senomyx, Sorrento Therapeutics, Tenax Therapeutics, and Charles River

NEW YORK, February 26, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including PAREXEL (NASDAQ: PRXL), Senomyx (NASDAQ: SNMX), Sorrento Therapeutics (NASDAQ: SRNE), Tenax Therapeutics (NASDAQ: TENX), and Charles River (NYSE: CRL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

PRXL Research Report: ( http://get.analystsreview.com/pdf/?c=PAREXEL&d=26-Feb-2015&s=PRXL ),

SNMX Research Report: ( http://get.analystsreview.com/pdf/?c=Senomyx&d=26-Feb-2015&s=SNMX ),

SRNE Research Report: ( http://get.analystsreview.com/pdf/?c=Sorrento%20Therapeutics&d=26-Feb-2015&s=SRNE ),

TENX Research Report: ( http://get.analystsreview.com/pdf/?c=Tenax%20Therapeutics&d=26-Feb-2015&s=TENX ),

CRL Research Report: ( http://get.analystsreview.com/pdf/?c=Charles%20River&d=26-Feb-2015&s=CRL ).

============

Analyst Update: Financial Results, Patient Enrollment, Strategic Appointment, Network Expansion, and Upcoming Results

Reviewed by: Rohit Tuli, CFA®  

U.S. stock markets witnessed a mixed trend on Wednesday as the Dow inched further into record territory but the Nasdaq broke its 10-day winning streak. The Dow Jones Industrial Average rose 15.38 points, or 0.08%, to 18224.57. The S&P 500 lost 1.62 points to 2113.86, while the Nasdaq Composite declined 0.98 points, or 0.02%, to 4967.14. Trading was relatively subdued ahead of the release of economic data on Thursday, as investors reviewed the latest corporate earnings news and digested remarks by Fed Chair. European stocks were down as mixed corporate results halted the rally that had propelled FTSE 100 and DAX to record highs. FTSE 100 was down 0.21% to 6935.38. Chinese stocks climbed to a four-week high amid speculation the nation will do more to support economic growth. China's HSBC/Markit Purchasing Managers' Index (PMI) inched up to 50.1 in February. Economists polled by Reuters had forecast a reading of 49.5, little changed from January's final PMI of 49.7. Japan's key Nikkei 225 index fell 0.1% and Australia's benchmark S&P ASX 200 index gained 0.3%.

PAREXEL International Corporation (PAREXEL) announced the continued expansion of its clinical trial Site Alliance Network, which enables PAREXEL to quickly access and enroll patient populations for clients' clinical trials worldwide - which is one of the most significant clinical trial challenges.

Senomyx, Inc. (Senomyx) has scheduled its Q4 2014 and full-year 2014 earnings conference call for February 26, 2015, before the opening of the U.S. financial markets. Senomyx will also host a conference call with a live Internet broadcast, which will provide a corporate update and a review of its fourth quarter and full-year results on the same day at 11:00 a.m. ET (8:00 a.m. Pacific Time).

Sorrento Therapeutics, Inc. (Sorrento Therapeutics) reported that the last patient in the ongoing TRIBECA™ (TRIal establishing bioequivalence [BE] between Cynviloq™ and Albumin-bound paclitaxel*) registrational trial has been randomized. The trial enrolled 111 patients in total globally from sites in USA, Eastern Europe, and Asia.

Tenax Therapeutics, Inc. (Tenax Therapeutics) announced the appointment of Paula Bokesch, M.D., as Chief Medical Officer, effective February 14, 2015. Dr. Bokesch will direct clinical development for the Company's lead asset, levosimendan, including the current Phase 3 LEVO-CTS trial to evaluate the use of levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS).

Charles River Laboratories International, Inc. (Charles River) reported fourth quarter financial results with revenue from continuing operations of $329.5 million, an increase of 13.9% YoY. The Company posted net income from continuing operations of $28.5 million, or $0.59 per diluted share, in Q4 2014, compared to $19.5 million, or $0.40 per diluted share, in Q4 2013.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review